Stocks and Investing
Stocks and Investing
Wed, April 5, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lebowitz Maintained (ASND) at Strong Buy with Decreased Target to $146 on, Apr 5th, 2023
David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Decreased Target from $163 to $146 on, Apr 5th, 2023.
David has made no other calls on ASND in the last 4 months.
There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $108 on, Tuesday, April 4th, 2023
- Tiago Fauth of "Credit Suisse" Downgraded from Buy to Hold on, Monday, April 3rd, 2023
These are the ratings of the 3 analyists that currently disagree with David
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $92 on, Tuesday, April 4th, 2023
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $163 on, Tuesday, January 17th, 2023
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023
Contributing Sources